Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2...

1
A 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 31% HLA-DR CD11b 41% 0 10 2 10 3 10 4 10 5 Ly6G + (E2) Ly6G + (Vh) B C Ly6C Ly6G 56.3% 4.0% 0.4% 1.1% Vh MPP SUPPLEMENTAL FIGURE 2

Transcript of Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2...

Page 1: Supplemental Figure 2 - Cancer Discovery · SUPPLEMENTAL FIGURE 2. Title: Supplemental Figure 2 Created Date: 7/29/2016 10:43:37 AM ...

A

0 102 103 104 105

0

102

103

104

105

<Pacific Blue-A>: CD11b

0 102 103 104 105

0

102

103

104

105

<Pacific Blue-A>: CD11b

31%

HLA-DR

CD

11b

41%

0 102103

104105

<CellTraceViolet-A>: Cell Trace

Ly6G+ (E2)

Ly6G+ (Vh)

B

C

Ly6C

Ly6G

56.3%

4.0% 0.4%

1.1%

Vh MPPSUPPLEMENTAL FIGURE 2

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Figure 2. Psychophysiological interaction ...

Supplemental Figure 2. Psychophysiological interaction ...

Supplemental Figure 2

Supplemental Figure 2

SUPPLEMENTAL INFORMATION 1. Supplemental …misclab.umeoce.maine.edu/documents/BehrenfeldBoss2014...Supplemental Figure 2. Identifying bloom initiation during exponential growth. Using

SUPPLEMENTAL INFORMATION 1. Supplemental …misclab.umeoce.maine.edu/documents/BehrenfeldBoss2014...Supplemental Figure 2. Identifying bloom initiation during exponential growth. Using

Supplemental figure 2.

Supplemental figure 2.

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure 2

Supplemental Figure 2

Supplemental digital content€¦ · Web viewSupplemental Figure 1. Figure that demonstrates co-cited authors that analyzed by CiteSpace. Supplemental Figure 2. Figure that demonstrates

Supplemental digital content€¦ · Web viewSupplemental Figure 1. Figure that demonstrates co-cited authors that analyzed by CiteSpace. Supplemental Figure 2. Figure that demonstrates

Supplemental Figure 1, related to Figure 1genesdev.cshlp.org/.../Supplemental_Figures.pdf · Supplemental Figure 2, related to Figure 2 (A-B) Full sequences of mouse Dll4in3 enhancer

Supplemental Figure 1, related to Figure 1genesdev.cshlp.org/.../Supplemental_Figures.pdf · Supplemental Figure 2, related to Figure 2 (A-B) Full sequences of mouse Dll4in3 enhancer

Supplemental Information Table of Contents Supplemental ...genesdev.cshlp.org/.../Supplemental_Data.pdf · Qiao_Supplemental Figure 2, related to Figure 2. (A) Loss of REDD1 confers

Supplemental Information Table of Contents Supplemental ...genesdev.cshlp.org/.../Supplemental_Data.pdf · Qiao_Supplemental Figure 2, related to Figure 2. (A) Loss of REDD1 confers

Supplemental Figures S1-S8. Supplemental Figure S1.

Supplemental Figures S1-S8. Supplemental Figure S1.

Supplement Supplemental Figures and Supplemental Figure ...

Supplement Supplemental Figures and Supplemental Figure ...

Supplemental Figure S1 .

Supplemental Figure S1 .

Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Supplemental Figure 1.

Supplemental Figure 1.

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental Figure 5

Supplemental Figure 5

Supplemental Figure 1

Supplemental Figure 1

Supplemental Figure legends (revision-2) · Supplemental Figure legends Supplemental Fig. 1 Gating strategy for isolation of regulatory T cells. (A) A gate surrounding CD3-positive

Supplemental Figure legends (revision-2) · Supplemental Figure legends Supplemental Fig. 1 Gating strategy for isolation of regulatory T cells. (A) A gate surrounding CD3-positive